Erratum: Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry [J Neurooncol, 116, (2014), 413-419, DOI 10.1007/s11060-013-1316-y];Efficacy of erlotinib in patients with relapsed gliobastoma multiforme who expressed EGFRVIII and PTEN determined by immunohistochemistry

Journal of Neuro-Oncology

Volumn 116, Issue 2, 2014, Pages 413-419

  Gallego, Oscar ^a   Cuatrecasas, M ^b   Benavides, M ^c   Segura, P P ^d   Berrocal, A ^e   Erill, N ^f   Colomer, A ^f   Quintana, M J ^a   Balana C ^g   Gil, M ^h   Gallardo, A ⁱ   Murata, P ^a   Barnadas, A ^a  

^a HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

^c HOSPITAL REGIONAL UNIVERSITARIO DE MÁLAGA   (Spain)

^d HOSPITAL CLÍNICO SAN CARLOS   (Spain)

^e H Gral Univ   (Spain)

^f Althia Advanced Laboratories of Translational Health   (Spain)

^g HOSPITAL UNIVERSITARI GERMANS TRIAS I PUJOL   (Spain)

^h CATALAN INSTITUTE OF ONCOLOGY   (Spain)

ⁱ HOSPITAL JOSEP TRUETA   (Spain)

Author keywords

Deep vein thrombosis (DVT); Enzyme inducing anti epileptic drugs (EIAEDs); Epidermal growth factor receptor (EGFR); Glioblastoma (GBM); Karnofsky performance status (KPS); Low molecular weight heparin (LMWH); Progression free survival (PFS6)

Indexed keywords

BEVACIZUMAB; CARMUSTINE; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 8; ERLOTINIB; IRINOTECAN; LOMUSTINE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROCARBAZINE; TEMOZOLOMIDE; UNCLASSIFIED DRUG; VINCRISTINE;

ADULT; ARTICLE; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; DERMATITIS; DIARRHEA; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG RESPONSE; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KARNOFSKY PERFORMANCE STATUS; MALE; MIDDLE AGED; MONOTHERAPY; PHASE 2 CLINICAL TRIAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; PROTEIN EXPRESSION;

BRAIN NEOPLASMS; FEMALE; HEMANGIOPERICYTOMA; HUMANS; KAPLAN-MEIER ESTIMATE; MALE; NEOPLASM RECURRENCE, LOCAL; RADIOSURGERY;

EID: 84893677705     PISSN: 0167594X     EISSN: 15737373     Source Type: Journal    
DOI: 10.1007/s11060-014-1643-7     Document Type: Erratum

References (22)

1. Rich JN, Reardon DA, Peery T, Dowell JM et al (2004) Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol 22:133-142
2. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA et al (2005) Molecular determinants of the response of glioblastoma to EGFR kinase inhibitors. N Engl J Med 353:2012-2024
3. Haas-Kogan DA, Prados MD, Tihan T, Eberhard DA et al (2005) Epidermal growth factor receptor, protein kinase B/Akt, and glioma response to erlotinib. J Natl Cancer Inst 97:880-887
4. Pelloski CE, Ballman KV, Furrth AF, Zhang L et al (2007) Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J Clin Oncol 25:2288-2295
5. Van den Bent MJ, Brandes A, Rampling R, Kouwenhoven MC et al (2009) Randomized phase II trial of erlotinib (E) vs. temozolomide (TMZ) or BCNU in recurrent glioblastoma multiforme (GBM): EORTC Brain Tumor Group Study 26034. J Clin Oncol 10(27):1268-1274
6. Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P et al (2010) Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol 12:1061-1070
7. Jeffrey J, Raizer, Lauren E, Andrew B, Chang SM et al (2010) A phase II trial of erlotinib in patients with recurrent malignant gliomas and non progressive glioblastoma multiforme postradiation therapy. J Neuro Oncol 12:95-103
8. Nguyen TD, Lassman AB, Lis E, Rosen N et al (2006) A pilot study to assess the tolerability and efficacy of RAD-001 (everolimus) with gefitinib in patients with recurrent glioblastoma multiforme (GBM). J Clin Oncol 24(18):1507. 2006 ASCO Annual Meeting Proceedings Part I
9. Doherty L, Gigas DC, Kesari S, Drappatz J et al (2006) Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67:156-158
10. De Groot JF, Gilbert MR, Hess KR, Hess KR et al (2008) Phase II study of combination carboplatin and erlotinib in patients with recurrent glioblastoma multiforme. J Neurooncol 90:89-97
11. Reardon DA, Desjardins A, James J, Gururangan S et al (2010) Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. J Neurooncol 96:219-230
12. Sathornsumetee S, Desjardins A, Vredenburgh JJ, McLendon RE et al (2010) Phase II trial of bevacizumab and erlotinib in patients with recurrent malignant glioma. Neuro Oncol 12:1300-1310
13. Hidalgo M, Siu LL, Nemunaitis J et al (2001) Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279
14. Schaiquevich P, Panetta JC, Throm S et al (2008) Pharmacokinetic analysis of erlotinib and OSI-420 in pediatric patients with malignant gliomas (Abstract). Nature 83:S51
15. Togashi Y, Masago K, Masuda S, Mizuno T et al (2012) Cerebrospinal fluid concentration of gefitinib and erlotinib in patients with non-small cell lung cancer. Cancer Chemother Pharmacol 70:399-405
16. Vivanco1 I, Ian Robins11 H, Rohle D, et al. Differential sensitivity of glioma-versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012;2:458
17. Gerlinger M, Rowan AJ, Horswell S, Larkin J et al (2012) Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Engl J Med 366:883-892
18. Brennan CW, Verhaak RG, McKenna A, Campos B, TCGA Research Network et al (2013) The somatic genomic landscape of glioblastoma. Cell 155:462-477
19. Yoshimoto K, Dang J, Zhu S, Nathanson D et al (2008) Development of a Real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res 14:488-493
20. Bianco R, Shin I, Ritter CA et al (2003) Loss of PTEN/MMAC1/TEP in EGF receptor-expressing tumor cells counteracts the anti tumor action of EGFR tyrosine kinase inhibitors. Oncogene 22:2812-2822
21. Pallares J, Bussaglia E, Martínez-Guitarte JL, Dolcet X, Llobet D, Rue M, Sanchez-Verde L, Palacios J, Prat J, Matias-Guiu X (2005) Immunohistochemical analysis of PTEN in endometrial carcinoma: a tissue microarray study with a comparison of four commercial antibodies in correlation with molecular abnormalities. Mod Pathol 18:719-727
22. Lv S, Teugels E, Sadones J, De Brakeleer S, Duerinck J, Du Four S, Michotte A, De Grève J, Neyns B (2012) Correlation of EGFR, IDH1 and PTEN status with the outcome of patients with recurrent glioblastoma treated in a phase II clinical trial with the EGFR-blocking monoclonal antibody cetuximab. Int J Oncol 41:1029-1035